CC
CPIX icon

Centiva Capital’s Cumberland Pharmaceuticals CPIX Stock Holding History

Centiva Capital’s Portfolio CPIX Stock Details CPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,000
Closed -$84.6K – 1619
2025
Q1 		$84.6K Buy
+20,000
New +$82.9K ﹤0.01% 1413

Other funds holding CPIX

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Centiva Capital's CPIX Position: Q2 2025 in Review

Centiva Capital sold out of Cumberland Pharmaceuticals (CPIX) in Q2 2025, closing a stake of 1,600 shares — an estimated $6.77K sold.

Centiva Capital first reported a position in CPIX in Q1 2025 and held it in 1 quarter. The position peaked at $6.77K in Q1 2025. 31 funds tracked by Wall St. Rank hold CPIX as of Q2 2025.

  • Centiva Capital reported no remaining Cumberland Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Centiva Capital sold 1,600 Cumberland Pharmaceuticals shares in Q2 2025, an estimated $6.77K.
  • Centiva Capital first reported a position in Cumberland Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Centiva Capital's Cumberland Pharmaceuticals position peaked at $6.77K in Q1 2025.
  • 31 funds tracked by Wall St. Rank held Cumberland Pharmaceuticals as of Q2 2025.

Based on Centiva Capital's 13F filing for Q2 2025, filed 13 Aug 2025.